Company / Interest Expense
Sunshine Biopharma Inc. Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$39.4K
FY2023
5-year range
$39.4K / $328.8K
FY2019-FY2023
Trend
-88.0%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Interest Expense has fluctuated over the past 8 years, ranging from $34,732 in FY2017 to $328,818 in FY2022.
Based on SEC 10-K filings.
$39,412 in FY2023 with a 5-year CAGR of -17.8%.
Improved from $168,105 to $39,412 over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -30.2%
- 5-Year CAGR
- -17.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -17.8%, indicating a declining trend.
- In FY2023, interest expense decreased 88.0% year-over-year.
- Peak interest expense was recorded in FY2022.
- Lowest interest expense in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $39.4K | -88.0% |
| FY2022 | $328.8K | +95.6% |
| FY2021 | $168.1K | +45.0% |
| FY2020 | $115.9K | -19.2% |
| FY2019 | $143.5K | +36.9% |
| FY2018 | $104.8K | +201.8% |
| FY2017 | $34.7K | -88.7% |
| FY2016 | $307.2K | +118.0% |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026